A

Adaptive Biotechnologies

Decoding the Immune System

Seattle, WA
700+

About Adaptive Biotechnologies

Industry: Immunomics/Diagnostics
Founded: 2009
Founders: Chad Robins, Harlan Robins
Status: Public (NASDAQ: ADPT)

Funding & Growth

Total Raised: $500M+
Valuation: $1.5B+ market cap
Stage: Public
Key Investors:
Madrona Venture Group Viking Global Genentech

✓ Pros

  • • Unique immune sequencing platform
  • • Microsoft partnership
  • • Seattle tech/biotech hub
  • • Clinical and research applications
  • • Strong science culture

✗ Cons

  • • COVID test revenue decline
  • • Market volatility
  • • Competitive diagnostics market
  • • Path to profitability

Get weekly job alerts